

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Applicati n Number	10/693,301
Filing Dat	October 24, 2003
First Nam d Inventor	Gary K. SCHWARTZ
Art Unit	
Examiner Name	
Attorney Docket Number	702-A-US

Sheet 1 of 3

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PCW	1	L. Zhang, L. Yank, X. Zheng, "A study of helicobacterium pylori and prevention and treatment of chronic atrophic gastritis", J. Tradit. Chin. Med., 17:3-9, 1997.	
PCW	2	L.Q. Yang, M. Singh, E.H. Yap, G.C. Ng, H.X. Xu, and K.Y. Sim, "In vitro response of Blastocystis hominis against traditional Chinese medicine", J. Ethnopharmacol 55: 35-42, 1996.	
PCW	3	S.G. Franzblau and C. Cross, "Comparative in vitro antimicrobial activity of Chinese medicinal herbs. J. Ethnopharmacol", 15: 279-288, 1986.	
PCW	4	L.C. Song, K.Z. Chen, J.Y. Zhu, "The effect of Coptis chinensis on lipid peroxidation and antioxidases activity in rats", Chung Kuo Chung Hsi I Chieh Ho Tsa Chih (1992 Jul) 12(7):421-3, 390.	
PCW	5	M. Umeda, S. Amagaya and Y. Ogihara, "Effects of certain herbal medicines on the biotransformation of arachidonic acid: a new pharmacological testing method using serum", J Ethnopharmacol (1988 May-Jun) 23(1):91-8.	
	6	G.D. Wang, Y.M. Zhang and X.Y. Xiong, "Clinical and experimental study of burns treated locally with Chinese herbs", Chung Hsi I Chieh Ho Tsa Chih (1991 Dec) 11(12):727-9, 709.	
PCW	7	W.M. Huang, J. Yan, and J. Xu, "Clinical and experimental study on inhibitory effect of sanhuang mixture on platelet aggregation", Chung Kuo Chung Hsi I Chieh Ho Tsa Chih (1995 Aug) 15(8):465-7	
	8	Y. Kobayashi, Y. Yamashita, N. Fuji, K. Takaboshi, T. Kawakami, M. Kamwamura, T. Mizukami, and H. Nakano, "Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes", Planta Med 61: 414-418, 1995	
PCW	9	X.P. Fang, T.Z. Wang, H. Shang, H. Shual, D. Li, and C.K. Xie, "Quantitative determination of 5 alkaloids in plants of coptis from china". Chung Kuo Yao Tsa chih 14: 33-35, 1989	
PCW	10	C.W. Chi, Y.F. Chang, T.W. Cjao, S.H. Chiang, F.K. P'eng, W.Y. Lui, and T.Y. Liu, "Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells". Life Sci 54: 2099-2107, 1994	

Examiner Signature	<i>Paul C...</i>	Date Considered	10/14/05
--------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/693,301
		Filing Date	October 24, 2003
		First Name and Inventor	Gary K. SCHWARTZ
		Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number		702-A-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PC	11	M. Fukutake, S. Yokota, H. Kawamura, A. Iizuka, S. Amagaya, K. Fukuda, and Y. Komatsu, "Inhibitory effect of Coptidis Rhizoma and Scutellariae Radix on azoxymethane-induced aberrant crypt foci formation in rat colon", Bio. Pharm Bull 21: 814-817, 1998	
PC	12	C.L. Qin, J.Y. Liu, and Z.M. Cheng, "Pharmacological studies on the effect of huanglian decoction on experimental gastric lesions in rats and antiemetic in pigeons", Chung Kuo Chung Yao Tsa Chih 19: 427-430, 1994	
PC	13	C.Y. Yeung, F.T. Lee, and H.N. Wong, "Effect of a Popular Chinese Herb on Neonatal Bilirubin Protein Binding", Biol Neonate 58: 98-103, 1990	
PC	14	E. Chan, "Displacement of bilirubin from albumin by berberine", Biol Neonate (1993) 63(4):201-8	
PC	15	J.A. Marin-Neto, B.C. Maciel, A.L. Seecches, and L. Gallo, "Cardiovascular effects of berberine in patients with severe congestive heart failure", Clin Cardiol 11: 253-260, 1988	
PC	16	X. Zeng and X. Zeng, "Relationship between the clinical effect of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC". Biomed Chromatogr 13: 442-444, 1999	
PC	17	X.S. Gao, "Absorptive capacity of upper gastrointestinal tract with Chinese herbal medicine", Chung Kuo Chung Hsi I Chieh Ho Tsa Chih (1993 Jul) 13(7):433-5, 390	
PC	18	Y. Ozaki, H. Suzuki, and M. Satake, "Comparative studies on concentration of berberine in plasma after oral administration of coptidis rhizoma extract, its cultured cells extract and combined use of these extracts and glycyrrhizal radix extract in rats", Yakugaku Zasshi 113: 63-69, 1993	
PC	19	P. Nurse, "Universal control mechanism regulating onset of M phase nature", (Lond) 344: 503-508, 1990	
PC	20	W-C Chuang, D-S Young, L.K. Liu, and S-J Sheu, "Liquid chromatography-electrospray mass spectrometric analysis of coptidis Rhizoma", J. Chromatogr 755L 19-26, 1996	

Examiner Signature	<i>Paul C</i>	Date Considered	10/14/05
--------------------	---------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/693,301
Filing Date	October 24, 2003
First Named Inventor	Gary K. SCHWARTZ
Art Unit	
Examiner Name	
Attorney Docket Number	702-A-US

Sheet 3 of 3

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PCW	21	C.M. Chen, H.C. Chang, "Determination of berberine in plasma, urine, and bile by HPLC", J. Chromatogr. 117-123, 1995	
PCW	22	H. Zhang, T. Want, X. Fang, H. Shuai, and C. Xie, "Plants of coptis from tibet and yunnan", Chung Kuo Chung Yao Tsa Chih China Journal Of Chinese Materia Medica. 15: 326-328, 1990	
PCW	23	D.L. Walker, J.M. Reid, and M.M. Ames, "Preclinical Pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065", Cancer Chemother Pharmacol 34: 317-322, 1994	

Examiner Signature	<i>Paul C...</i>	Date Considered	10/14/05
--------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 13-881 TO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/693,301
Filing Date	October 24, 2003
First Named Inventor	Gary K. Schwartz
Art Unit	
Examiner Name	
Attorney Docket Number	702-A-US

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
Ren	1	PCT/CN01/01521	10-10-02	LI, HONGFEN		

**Examiner  
Signature**


Date  
Considered

10/14/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/693,301
Filing Date	October 24, 2003
First Named Inventor	Gary K. SCHWARTZ
Art Unit	
Examiner Name	
Attorney Docket Number	702-A-US

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s); volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PCW	2	PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Filed on October 25, 2003, Dated May 11, 2004.	
PCW	3	Database PGPB on WEST, BASu et al. Treatment for Inflammatory bowel disease (IBD) and related conditions. PGPUB-DN 20020025348; February 26, 2003, Sections 0047-0048 and also claim 2.	
PCW	4	Database PGPB on WEST, LU et al. Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract. PGPUB-DN 20020182274, December 5, 2002, entire document.	

Examiner Signature	<i>Paul C...</i>	Date Considered	10/14/05
-----------------------	------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.